ZNF217 is a zinc finger transcription factor that functions primarily as a transcriptional repressor with significant oncogenic properties 1. The protein binds to specific DNA sequences and recruits co-repressor complexes to repress target gene transcription 1. ZNF217 is located on chromosome 20.2, a region frequently amplified in 20-30% of early-stage breast cancers and associated with poor prognosis 1. The protein promotes cell proliferation and survival by attenuating apoptotic signals, including resistance to chemotherapy agents like doxorubicin 1. In cancer contexts, ZNF217 functions as a core transcriptional regulatory circuit component, particularly in acute myeloid leukemia where it directly regulates MYB expression 2 and in high-risk B-cell acute lymphoblastic leukemia where it controls cell survival through both CoREST-dependent and independent mechanisms 3. Beyond oncology, ZNF217 plays roles in reproductive biology, where reduced expression in polycystic ovary syndrome affects androgen production through regulation of DENND1A.V2 and miR-130b-3p 4. The protein also contributes to ovarian hyperstimulation syndrome by promoting estradiol synthesis and regulating vascular permeability 5. These diverse functions establish ZNF217 as both a key oncogenic factor and potential therapeutic target across multiple human diseases 67.